Evaluation of the Neutron™ needlefree catheter patency device technology and resistance to microbial ingress

Report of a study commissioned by ICU and conducted by AAIPharma Services

BACKGROUND
The CDC estimates that there are approximately 250,000 incidents of Catheter Related Bloodstream Infections (CRBSIs) annually in the United States.\(^1\) Although the attributable mortality due to CRBSIs is not clear, these infections have been associated with higher costs, mortality rates, and number of hospital-days.\(^1,2\) Among the circumstances which risk the safe use of catheters are microbial ingress and intraluminal thrombotic occlusion, which result from clot formation in the lumen or tip of the catheter or needlefree connector due to the presence of blood.

The Neutron is a microbiologically and mechanically closed needlefree connector, which permits access to the catheter via use of a luer lock connection. Additionally, the Neutron catheter patency device is the first and only FDA-cleared device shown to significantly reduce all types of reflux into a catheter while maintaining a microbial barrier. The Neutron prevents the reflux of blood into the catheter, which can otherwise lead to thrombotic occlusion and loss of patency.

The U.S. Food and Drug Administration (FDA) classifies needlefree connectors as a class II medical device that requires clearance from the agency in accordance with the published guidance document; Intravascular Administration Sets Premarket Notification Submission [510(K)].\(^3\) This document requires that all new needlefree connectors seeking approval to include a microbial ingress study as part of the submission. ICU Medical independently contracted with AAIPharma Services in Wilmington, North Carolina, to perform the required testing. The results are reported herein.

PURPOSE
Intravenous (IV) therapy is the primary route for therapeutic regimens in the acute care setting. Nearly all hospitalized patients have some type of vascular access device inserted to support their treatment. As reliance on the IV pathway has increased, the potential for accidental needlestick injuries led to the creation of luer-activated needlefree connectors. These devices are used to connect catheters, administration sets, and/or syringes to deliver IV therapy. Unfortunately, placement of a vascular access device increases the risk of a bloodstream infection. In fact, approximately 87 percent of bloodstream infections are associated with the presence of some type of intravascular device.\(^4\) There are two primary portals for bacterial ingress into the bloodstream through a catheter—the first being the insertion site, and the second being the hub, where the needlefree connector is placed as the access port. The need to effectively prevent bacterial ingress through the needlefree connector is paramount in helping to prevent bloodstream infection.

In compliance with FDA guidance, microbial ingress testing evaluates a product’s design and its ability to resist the passage of microorganisms under a simulated use model. The intent of the study is to demonstrate that the device will act as a barrier to intraluminal bacterial contamination under normal use. Specifically, microbial ingress testing should demonstrate that if the device were disinfected by manual scrubbing using a standard disinfectant, then the subsequent connection using a sterile device would not transmit bacteria. The FDA recommends testing new devices under extreme use conditions, such as repeated insertions into the female luer or split-septum and static insertion over a period of hours.

Development of the methods and protocols in this white paper were based on the 2008 FDA guidance including a test period of 72 hours and the testing of at least 4 different bacteria, including Gram negative and Gram positive strains.

MATERIALS AND METHODS
In order to assess whether the septum of the Neutron connector can be effectively disinfected with 70 percent isopropyl alcohol (IPA) and maintain a physical barrier to bacteria, a protocol was developed and executed by AAIPharma Services using four bacterial strains:
Staphylococcus epidermidis, ATCC #12228
Staphylococcus aureus, ATCC #6538
Klebsiella pneumonia, ATCC #4352
Pseudomonas aeruginosa, ATCC #9027

Twenty-four (24) test samples were prepared in addition to eight (8) negative control samples and eight (8) positive control samples. Each sample device was subjected to 5 inoculations/disinfections/activations per 24-hour period for 3 days. After the 15th activation, 2 additional activations were performed: one four-hour “extended activation” and one final activation in which 10 mL of soybean casein digest broth (SCDB) with 5% deactivated bovine serum albumin was flushed through the device. Testing was performed per AAIPharma Protocol ICMS122809.

Over a three-day period, this experiment utilized artificial contamination of the Neutron septum with inoculum level of at least $10^3$ organisms to simulate extreme-use conditions. Each sample was subjected to inoculation and allowed to dry for at least 1 minute, followed by standard hospital disinfection procedure using a 70% (IPA) prep pad and wiping vigorously in a circular motion for three seconds. This entire process was completed five (5) times per 24-hour period. After each engagement, injectate through the connector was collected and tested for the presence of the challenge microorganisms.

Positive controls included in this study were inoculated with the same number of organisms as the test samples, but were not subjected to the disinfection process prior to activation. Negative controls included in this study were not inoculated with any of the challenge organisms, but were subjected to the same disinfection and activation processes as the sample units. All negative control samples were negative for ingress of any of the challenge organisms.

RESULTS

Of the four bacterial strains, the data indicates that zero (0) colony-forming unit (CFU) of each test organism passed through the septum of the Neutron needlefree connector for all 17 activations to which each of the 24 test samples were subjected. (See Table.)

<table>
<thead>
<tr>
<th>Test Organism</th>
<th>Extended Activation (CFU)</th>
<th>SCDB Flush (CFU)</th>
<th>Positive Control Log Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Staphylococcus epidermidis</td>
<td>0</td>
<td>0</td>
<td>3.3</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>0</td>
<td>0</td>
<td>3.1</td>
</tr>
<tr>
<td>Klebsiella pneumonia</td>
<td>0</td>
<td>0</td>
<td>3.1</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>0</td>
<td>0</td>
<td>3.1</td>
</tr>
</tbody>
</table>

CONCLUSION

In all cases the microbial barrier of the Neutron needlefree catheter patency device effectively prevented microbial ingress when inoculated with at least 3 logs of organism and challenged under simulated extreme-use conditions, including repeated inoculation on the outer surface of the septum, disinfection, and activation over a period of 3 days. Furthermore, the results confirm that the Neutron microbial barrier meets the requirements delineated by the 2008 FDA guidance document Intravascular Administration Sets Premarket Notification Submissions [510(k)]. The Neutron may be considered an effective tool to assist in the prevention of catheter hub contamination and otherwise intraluminal bacterial colonization.

References